Paroxetine retards disease onset and progression in Huntingtin mutant mice
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
We report that administration of paroxetine, a widely prescribed antidepressant drug that acts by inhibiting reuptake of the neurotransmitter serotonin, suppresses the neurodegenerative process and increases the survival of huntingtin mutant mice, an animal model of Huntington's disease (HD). Paroxetine attenuated motor dysfunction and body weight loss and improved glucose metabolism in the HD mice. Paroxetine was beneficial when treatment was initiated before or after the onset of motor dysfunction, suggesting a potential for such antidepressant drugs in the treatment of presymptomatic and symptomatic HD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nibuya, M., Nestler, E., & Duman, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-07-02365.1996 · Cited by 1,206
Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · cited 5×
“We previously reported that the HD mice exhibit progressive weight loss.(9) HD mice given paroxetine lost weight at a significantly slower rate than did vehicle-treated HD mice (see Fig 1C).”
BackgroundMethodInfluentialSelf-citationSchilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151
Fluoxetine in the treatment of Huntington’s disease
De Marchi, N., Daniele, F., & Ragone, M. A. (2001) · Psychopharmacology · doi:10.1007/s002130000575 · Cited by 57
Cited by
Mitochondria in neuroplasticity and neurological disorders
Mattson, M. P., Gleichmann, M., & Cheng, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.010 · Cited by 1,081
Self-citationAgeing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Self-citationBDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders
Mattson, M. P., Maudsley, S., & Martin, B. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.001 · Cited by 942
Self-citationMolecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
“Antidepressants, such as paroxetine and sertraline (selective serotonin reuptake inhibitors), also increase endogenous BDNF levels and prolong survival of neurons, improve motor performance, and ameliorate brain atrophy in N171–82Q mice (159, 161).”
BackgroundGlutamate and Neurotrophic Factors in Neuronal Plasticity and Disease
Mattson, M. P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.005 · Cited by 640
Self-citationRole of brain-derived neurotrophic factor in Huntington's disease
ZUCCATO, C., & CATTANEO, E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.01.003 · Cited by 552
Mattson, M. P., & Wan, R. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.12.007 · Cited by 469
Self-citationJiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., Xiang, L., Peng, Q., Hou, Z., Cai, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2558 · Cited by 345
Self-citationMattson, M. P., Maudsley, S., & Martin, B. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2004.08.001 · Cited by 268
Self-citationENERGY INTAKE, MEAL FREQUENCY, AND HEALTH: A Neurobiological Perspective
Mattson, M. P. (2005) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.25.050304.092526 · Cited by 258
Self-citationMager, D. E., Wan, R., Brown, M., Cheng, A., Wareski, P., Abernethy, D. R., & Mattson, M. P. (2006) · The FASEB Journal · doi:10.1096/fj.05-5263com · Cited by 255
Self-citationHannan, A. J. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12102 · Cited by 240
Cognitive disorders and neurogenesis deficits in Huntington’s disease mice are rescued by fluoxetine
Grote, H. E., Bull, N. D., Howard, M. L., Van Dellen, A., Blakemore, C., Bartlett, P. F., & Hannan, A. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04365.x · Cited by 179
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
NELSON, R., GUO, Z., HALAGAPPA, V, PEARSON, M., GRAY, A., MATSUOKA, Y., BROWN, M., MARTIN, B., IYUN, T., & MAUDSLEY, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.01.037 · Cited by 173
“, 2002; Bourin, 2003), but may also have therapeutic potential as neuroprotective agents (Sanchez et al., 2001; Duan et al., 2004).”
BackgroundSelf-citationPeng, Q., Masuda, N., Jiang, M., Li, Q., Zhao, M., Ross, C. A., & Duan, W. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.10.015 · Cited by 173
“We previously showed that the SSRI paroxetine is neuroprotective in the N171-82Q HD mice (Duan et al., 2004).”
BackgroundSelf-citationTherapeutic Advances for Huntington’s Disease
Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J. (2020) · Brain Sciences · doi:10.3390/brainsci10010043 · Cited by 164
Results of the citalopram to enhance cognition in Huntington disease trial
Beglinger, L. J., Adams, W. H., Langbehn, D., Fiedorowicz, J. G., Jorge, R., Biglan, K., Caviness, J., Olson, B., Robinson, R. G., Kieburtz, K., et al. (2014) · Movement Disorders · doi:10.1002/mds.25750 · Cited by 65
Choe, Y. M., Kim, K. W., Jhoo, J. H., Ryu, S. H., Seo, E. H., Sohn, B. K., Byun, M. S., Bak, J., Lee, J., Yun, H. J., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4384 · Cited by 31
“…investigating Huntingtin mutant mice demonstrated that the administration of paroxetine decelerates the neurodegenerative disease process itself (Duan et al., 2004), and another study found that administration of paroxetine even suppresses amyloid-β and tau pathology in a mouse model of AD…”
Background
Metadata
- Authors
- Duan, W., Guo, Z., Jiang, H., Ladenheim, B., Xu, X., Cadet, J. L., & Mattson, M. P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2004-03-22
- Volume
- 55
- Issue
- 4
- Pages
- 590-594
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2147579853
- Cited by
- 91
- References
- 6
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.